BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 21, 2004
View Archived Issues
Tarceva Phase III: 'Modest' Benefit In Pancreas Cancer
Already strong in lung cancer, Tarceva proved its mettle in a Phase III study combined with gemcitabine as a first-line therapy against pancreatic cancer, meeting the primary endpoint of survival improvement. (BioWorld Today)
Read More
Medarex Partners With Pfizer In Potential $510M Antibody Deal
Read More
Phase III Miss For Ceplene Halves Maxim's Stock Price
Read More
Acambis Falls On Cancelled Smallpox Contract From CDC
Read More
Other News To Note
Read More